30 closest matches · ranked by relevance
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Stage III Distal Bile Duct Cancer AJCC v8 · Stage III Gallbladder Cancer AJCC v8 · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Overall Survival (OS) — 14.0; 13.6 months — p=0.41
Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma · Recurrent Adult Liver Carcinoma
Primary: Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 — 0 patients
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
Stage III Intrahepatic Cholangiocarcinoma AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7 · Stage IIIB Gallbladder Cancer AJCC v7
Primary: Median Progression Free Survival (PFS) — 11.4; 14.9 months — p=0.62
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg
Biliary Cancer · Cholangiocarcinoma
Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants
Cholangiocarcinoma
Primary: The Primary Objective of This Study is to Assess Progression Free Survival (PFS) With Proposed Therapy for Patients With Locally Advanced or Metastatic Gallbladder and…
Cancer of the Bile Duct
Primary: Overall Survival (OS) at 6 Months — 7.9 months
Adenocarcinoma
Primary: Progression-free Survival (PFS) — 91; 148 days
Cholangiocarcinoma
Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants
Biliary Tract Neoplasms
Primary: The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment — 59.4; 21.2 percentage of participants
Bile Duct Cancer · Intrahepatic Cholangiocarcinoma · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Median Progression Free Survival (PFS) — 1.8 months
Biliary Tract Cancer · Gallbladder Cancer
Primary: The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response…
Biliary Tract Cancer · Biliary Tract Neoplasms
Primary: Overall Response Rate (ORR) After 4 Cycles of Treatment — 22 percent
Cholangiocarcinoma of the Extrahepatic Bile Duct · Cholangiocarcinoma of the Gallbladder · Gastrointestinal Cancer
Primary: Number of Confirmed Tumor Responses. — 6; 0 participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Response — 7; 6; 12; 15 participants
Advanced Bile Duct Carcinoma · Advanced Gallbladder Carcinoma · Refractory Bile Duct Carcinoma
Primary: Progression-free Survival (PFS) — 37.0 percentage of participants
Cholangiocarcinoma · Liver and Intrahepatic Bile Duct Carcinoma · Stage III Gallbladder Cancer AJCC v7
Primary: Progression Free Survival of Ramucirumab in Advanced Biliary Cancers — 3.2 months
Biliary Tract Cancer · Cholangiocarcinoma · Gallbladder Cancer
Primary: Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by…
Extrahepatic Bile Duct Adenocarcinoma · Gallbladder Adenocarcinoma · Gallbladder Adenocarcinoma With Squamous Metaplasia
Primary: Progression-free Survival — 2 months
Resectable Cholangiocarcinoma · Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 · Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants
Biliary Tract Cancer
Primary: Phase Ib: Incidence of Dose-limiting Toxicities (DLTs) of Drug Combination Nanoliposomal-Irinotecan, 5-fluorouracil, Leucovorin and Nivolumab — 4 Participants
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Response Rate — 0; 5 percentage of responding patients
Cholangiocarcinoma · Stage III Gallbladder Cancer AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7
Primary: 16-Week Progression-free Survival (PFS) Rate — 32.0 percentage of patients
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
Biliary Tract Cancer
Primary: Percentage of Patients Alive at 1 Year (1-Year Survival Rate) — 39; 31 percentage of participants
Liver and Intrahepatic Biliary Tract Cancer · Recurrent Extrahepatic Bile Duct Cancer · Unresectable Extrahepatic Bile Duct Cancer
Primary: Objective Response Rate (CR and PR) — 0; 3 patients
Periampullary Cancers With Obstructive Jaundice · Pancreas Head Cancer · Bile Duct Cancer
Primary: Incidence of Infectious Complications After Biliary Drainage — 11; 5 participants